Kamada Confirms Full-year Revenue Outlook

(RTTNews) - Kamada Ltd. (KMDA), a biopharmaceutical company, Wednesday said it continues to expect full-year revenue in the range of $158 million to $162 million.

Adjusted EBITDA, or adjusted earnings before interest, taxes, depreciation, and amortization for the year is still expected between $32 million and $35 million.

For fiscal 2025, the company sees revenue in the range of $178 million - $182 million and adjusted EBITDA of $38 million - $42 million.

The mid-point of the 2025 outlook represents an increase of 13 percent in revenues and 19 percent in adjusted EBITDA based on the mid-point of the 2024 guidance.